Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Neumora Therapeutics, Inc. (NMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NMRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.05
1 Year Target Price $7.05
| 1 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.69% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.43M USD | Price to earnings Ratio - | 1Y Target Price 7.05 |
Price to earnings Ratio - | 1Y Target Price 7.05 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 0.61 - 17.19 | Updated Date 06/30/2025 |
52 Weeks Range 0.61 - 17.19 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.51% | Return on Equity (TTM) -79.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -125987998 | Price to Sales(TTM) - |
Enterprise Value -125987998 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 161748000 | Shares Floating 85865502 |
Shares Outstanding 161748000 | Shares Floating 85865502 | ||
Percent Insiders 27.57 | Percent Institutions 60.21 |
Analyst Ratings
Rating 3 | Target Price 7.05 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neumora Therapeutics, Inc.
Company Overview
History and Background
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019, focused on developing novel therapies for brain diseases. The company aims to address unmet needs in neuropsychiatric disorders and neurodegenerative diseases.
Core Business Areas
- Neuropsychiatric Disorders: Developing therapies for major depressive disorder (MDD), schizophrenia, and other psychiatric illnesses.
- Neurodegenerative Diseases: Researching and developing treatments for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.
Leadership and Structure
The leadership team consists of experienced executives in drug development and commercialization. The organizational structure is typical of a biopharmaceutical company, with dedicated research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- Navacaprant: A Kappa Opioid Receptor (KOR) antagonist currently in Phase 3 development for Major Depressive Disorder (MDD). Market share data is not yet available as the product is not commercialized. Competitors include traditional antidepressants (SSRIs, SNRIs) and other novel therapies in development by companies like Axsome Therapeutics (AXSM).
- NMRA-266: A selective vasopressin 1A receptor (V1AR) antagonist in Phase 2 development for Social Anxiety Disorder (SAD). Market share data is not yet available. Competitors include SSRIs, SNRIs, and other anxiolytics. Companies like BioXcel Therapeutics (BTAI) are also developing treatments for anxiety disorders.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurological and psychiatric disorders is growing, driven by increasing prevalence and unmet medical needs. The industry is characterized by high research and development costs, regulatory hurdles, and competition.
Positioning
Neumora Therapeutics is positioned as an innovator in the neuropsychiatric and neurodegenerative disease space, focusing on novel targets and mechanisms of action. Its competitive advantage lies in its experienced team and promising pipeline.
Total Addressable Market (TAM)
The TAM for neuropsychiatric and neurodegenerative disease therapies is estimated to be hundreds of billions of dollars globally. Neumora is positioned to capture a portion of this market with successful development and commercialization of its pipeline assets.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel drug candidates
- Experienced management team
- Focus on unmet medical needs
- Strong financial backing
Weaknesses
- Clinical trial risks
- Regulatory hurdles
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expanding pipeline through internal research and development
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies or assets
- Expanding into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory environment
- Pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- AXSM
- BIIB
- VRTX
Competitive Landscape
Neumora competes with larger, more established pharmaceutical companies. Neumora's advantage lies in its novel targets and mechanisms of action, while its disadvantage is its limited resources and commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of pipeline candidates through clinical trials.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates will vary depending on the stage of clinical development.
Recent Initiatives: Recent initiatives include advancing Navacaprant into Phase 3 clinical trials, progressing NMRA-266, and securing additional funding.
Summary
Neumora Therapeutics is a promising biopharmaceutical company with a focus on developing novel therapies for brain diseases. Its success hinges on the positive outcomes of its clinical trials, particularly for its lead compound, Navacaprant. Although Neumora faces the typical challenges associated with clinical-stage companies, its strong pipeline and experienced management team provide a solid foundation for future growth. They need to successfully navigate regulatory hurdles and compete with established pharmaceutical players to realize its full potential. It is an early-stage company with plenty to prove.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2023-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://www.neumoratx.com |
Full time employees 103 | Website https://www.neumoratx.com | ||
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.